Immunological non-inferiority and safety of a quadrivalent inactivated influenza vaccine versus two trivalent inactivated influenza vaccines in China: Results from two studies

• Main Authors: Xiaoqiang Liu (Author), Juliana Park (Author), Shengli Xia (Author), Bin Liang (Author), Shuangmin Yang (Author), Yanxia Wang (Author), Olga Syrkina (Author), Nathalie Lavis (Author), Shuzhen Liu (Author), Chenyan Zhao (Author), Jian Ding (Author), Jieqiong Hu (Author), Sandrine I. Samson (Author), Iris A. de Bruijn (Author), for the FSQ01 and FSQ02 Study Groups (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

A quadrivalent, split-virion influenza vaccine (Shz QIV), containing two influenza A strains, and both B lineages strains, has been developed in China. We report the safety and immunogenicity of Shz QIV in two studies: a single-center, phase I, open-label, safety trial (n = 101) and a multicenter, p...